Brief: Edwards Sapien M3 Receives CE Mark, Becoming World’S First Transfemoral Transcatheter Mitral Valve Replacement System
14/04/2025 13:32
April 14 (Reuters) - Edwards Lifesciences Corp EW.N: EDWARDS SAPIEN M3 RECEIVES CE MARK, BECOMING WORLD’S FIRST TRANSFEMORAL TRANSCATHETER MITRAL VALVE REPLACEMENT SYSTEM Source text: ID:nBw14NngVa Further company coverage: EW.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Edwards Lifesciences
See all newsFDA flags Edwards heart-valve delivery system issue after death, injury (updated)
FDA flags Edwards heart-valve delivery system issue after death, injury
Brief: FDA Aware Edwards Lifesciences Issued Letter Recommending Some Delivery Systems Used For Sapien M3 Transcatheter Mitral Valve Replacement Be Removed
Brief: Edwards Lifesciences Corporation - Maintains Confidence In Financial Guidance For 2026
U.S. RESEARCH ROUNDUP-Deckers Brands, Rollins, United Rentals